We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Low Serum Glutathione Peroxidase Activity Increases Risk of Cardiovascular Disease in Individuals with Low HDL-cholesterol

By LabMedica International staff writers
Posted on 28 Jun 2012
A retrospective study of stored serum samples has found that individuals with low HDL-cholesterol (cholesterol associated with high-density lipoproteins) and low levels of the enzyme glutathione peroxidase (GPx3) suffered significantly more incidence of fatal cardiovascular disease than did those with low HDL-cholesterol but elevated levels of GPx3.

GPx3 is a natural antioxidant that contains a selenocysteine (Sec) residue at its active site. More...
One of its activities in the body is to reduce oxidized lipids, such as LDL (low-density lipoproteins), which have been linked to the development of atherosclerosis. This relationship to cardiovascular disease was the basis for a study conducted by investigators at the University of Minnesota (Minneapolis, USA) to determine whether high GPx3 activity could reduce cardiovascular disease (CVD) mortality.

The investigators evaluated 130 stored serum samples obtained during the Minnesota Heart Survey from participants aged 26-85 years who had died of cardiovascular disease after five to 12 years of follow-up care. Odds ratios (OR) were calculated after adjustment for age, sex, baseline year, body mass index, smoking, alcohol intake, physical activity, total and HDL-cholesterols, systolic blood pressure, serum glucose, and gamma glutamyltransferase (GTT) activity. Data was compared to that from 240 control samples from individuals without cardiovascular disease.

Results published in the June 15, 2012, online edition of the journal PLoS One revealed that individuals with low levels of HDL-cholesterol and GPx3 were six times more likely to die from cardiovascular disease, including heart attack or stroke, than those with low levels of HDL-cholesterol and high levels of GPx3. GPx3 levels were not linked significantly to risk of cardiovascular disease in individuals with high levels of HDL-cholesterol.

“In our study, we found that people with high levels of the GPx3 enzyme and low levels of good cholesterol were six times less likely to develop cardiovascular disease than people with low levels of both,” said senior author Dr. Jordan L. Holtzman, professor of pharmacology and medicine at the University of Minnesota. “This GPx3 enzyme gives us a good reason to believe that natural antioxidants like GPx3 are good for heart health. This is an important enzyme for people with low HDL-cholesterol. We think further research will be important in determining the future role of GPx3 and what drugs may serve to increase its activity in the blood.”

"It is important to point out that people should not rush out to their doctors and demand testing for the GPx3 enzyme,” said Dr. Holtzman. “But in time, we hope that measuring this enzyme will be a common blood test when determining whether a patient is at risk for cardiovascular disease, including heart attacks and strokes.”

Related Links:

University of Minnesota



Gold Member
Troponin T QC
Troponin T Quality Control
Serological Pipet Controller
PIPETBOY GENIUS
New
Hand-Held Immunofluorescence Analyzer
WS-Si1500
New
DNA/RNA Extraction/Purification Kit
Nucleic Acid Extraction or Purification Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.